The U.S. Food and Drug Administration has approved a blood test to be used for colorectal cancer screening among average-risk adults 45 and older.The maker of the test, Palo Alto, California-based biotechnology company Guardant Health, announced Monday that this is the first blood test to be approved by the FDA as a primary screening option for colorectal cancer, and it’s the first approved blood screening test for colorectal cancer that meets requirements for Medicare reimbursement. For patients with commercial insurance plans, the cost of the test may vary depending on their individual plan coverage. The list price for the test has not yet been announced.“This is a promising step toward making more convenient tools available to detect colorectal cancer early while it is more easily treated,” Dr. William M. Grady, a gastroenterologist at Fred Hutchinson Cancer Center, said in a statement Monday released by Guardant Health.In the United States, colorectal …